Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 44
Filtrar
Mais filtros











Intervalo de ano de publicação
2.
Vet Pathol ; 61(5): 752-764, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38533804

RESUMO

One of the most relevant prognostic indices for tumors is cellular proliferation, which is most commonly measured by the mitotic activity in routine tumor sections. The goal of this systematic review was to analyze the methods and prognostic relevance of histologically measuring mitotic activity that have been reported for canine tumors in the literature. A total of 137 articles that correlated the mitotic activity in canine tumors with patient outcome were identified through a systematic (PubMed and Scopus) and nonsystematic (Google Scholar) literature search and eligibility screening process. Mitotic activity methods encompassed the mitotic count (MC, number of mitotic figures per tumor area) in 126 studies, presumably the MC (method not specified) in 6 studies, and the mitotic index (MI, number of mitotic figures per number of tumor cells) in 5 studies. A particularly high risk of bias was identified based on the available details of the MC methods and statistical analyses, which often did not quantify the prognostic discriminative ability of the MC and only reported P values. A significant association of the MC with survival was found in 72 of 109 (66%) studies. However, survival was evaluated by at least 3 studies in only 7 tumor types/groups, of which a prognostic relevance is apparent for mast cell tumors of the skin, cutaneous melanoma, and soft tissue tumor of the skin and subcutis. None of the studies using the MI found a prognostic relevance. This review highlights the need for more studies with standardized methods and appropriate analysis of the discriminative ability to prove the prognostic value of the MC and MI in various tumor types. Future studies are needed to evaluate the influence of the performance of individual pathologists on the appropriateness of prognostic thresholds and investigate methods to improve interobserver reproducibility.


Assuntos
Doenças do Cão , Índice Mitótico , Neoplasias , Cães , Doenças do Cão/patologia , Doenças do Cão/diagnóstico , Animais , Prognóstico , Índice Mitótico/veterinária , Neoplasias/veterinária , Neoplasias/patologia , Neoplasias/diagnóstico , Mitose
3.
Vet Pathol ; 61(5): 743-751, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38533803

RESUMO

Increased proliferation is a driver of tumorigenesis, and quantification of mitotic activity is a standard task for prognostication. This systematic review is an analysis of all available references on mitotic activity in feline tumors to provide an overview of the assessment methods and prognostic value. A systematic literature search in PubMed and Scopus and a nonsystematic search in Google Scholar were conducted. All articles on feline tumors that correlated mitotic activity with patient outcome were identified. Data analysis revealed that of the 42 eligible articles, mitotic count (MC, mitotic figures/tumor area) was evaluated in 39 studies, and mitotic index (MI, mitotic figures/tumor cells) in 3 studies. The risk of bias was considered high for most studies (26/42, 62%) based on small study populations, insufficient details of the MC/MI methods, and lack of statistical measures for diagnostic accuracy or effect on outcome. The MC/MI methods varied between studies. A significant association of MC with survival was determined in 20 of 28 (71%) studies (10 studies evaluated other outcome metrics or provided individual patient data), while 1 study found an inverse effect. Three tumor types had at least 4 studies, and a prognostic association with survival was found in 5 of 6 studies on mast cell tumors, 5 of 5 on mammary tumors, and 3 of 4 on soft-tissue sarcomas. MI was shown to correlate with survival for mammary tumors by 2 research groups; however, comparisons to MC were not conducted. Further studies with standardized mitotic activity methods and appropriate statistical analysis for discriminant ability of patient outcome are needed to infer the prognostic value of MC and MI.


Assuntos
Doenças do Gato , Mitose , Neoplasias , Animais , Gatos , Doenças do Gato/patologia , Doenças do Gato/diagnóstico , Índice Mitótico/veterinária , Neoplasias/veterinária , Neoplasias/patologia , Neoplasias/diagnóstico , Prognóstico
4.
Vet Pathol ; 61(4): 534-540, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38214328

RESUMO

Canine splenic hemangiosarcoma has a high metastatic rate and short survival time. Currently, the main prognostic parameters are tumor stage and therapy, while data on histologic parameters, such as grade and Ki-67 expression, are scarce. The aims of this study were to compare two methods of assessment of Ki-67, verify their prognostic impact, and define a threshold value based on survival. Thirty-one cases of histologically diagnosed canine splenic hemangiosarcoma, which were treated with splenectomy and had full staging and follow-up information, were collected. Three were stage I, 17 stage II, and 11 stage III. The mean mitotic count (MC) was 23.9 (standard deviation [SD]: 22.1) and the median was 15 (range, 1-93). Immunohistochemistry for Ki-67 was performed, the Ki-67 labeling index (Ki-67LI) was assessed as a percentage of positive neoplastic nuclei per ≥500 cell, and the Ki-67 count (KI-67C) was defined as the average number of positive nuclei using a 1 cm2 optical grid performed in 5, 40× fields. The mean Ki-67LI and Ki-67C were 56.4% (SD: 38.7) and 27.2 (SD: 12.9) and medians were 51% (range, 8.2-55.2) and 26 (range, 5.5-148), respectively. Using a cut-off of 56% and 9, respectively, Kaplan-Meier survival curves showed an association of overall survival with Ki-67LI and MC. In addition to clinical stage, Ki-67LI maintained its prognostic value on multivariate analysis, supporting the role of Ki-67LI as an independent prognostic parameter. Based on these results, we propose a diagnostically applicable cut-off value of 56% for Ki-67LI as a prognostic parameter for canine splenic hemangiosarcoma.


Assuntos
Doenças do Cão , Hemangiossarcoma , Antígeno Ki-67 , Neoplasias Esplênicas , Hemangiossarcoma/veterinária , Hemangiossarcoma/patologia , Hemangiossarcoma/metabolismo , Hemangiossarcoma/diagnóstico , Animais , Antígeno Ki-67/metabolismo , Doenças do Cão/patologia , Doenças do Cão/metabolismo , Doenças do Cão/diagnóstico , Cães , Prognóstico , Neoplasias Esplênicas/veterinária , Neoplasias Esplênicas/patologia , Neoplasias Esplênicas/diagnóstico , Neoplasias Esplênicas/metabolismo , Masculino , Feminino , Imuno-Histoquímica/veterinária , Esplenectomia/veterinária , Índice Mitótico/veterinária , Estadiamento de Neoplasias/veterinária , Biomarcadores Tumorais/metabolismo
5.
J Comp Pathol ; 189: 77-87, 2021 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-34886989

RESUMO

Gastrointestinal lymphomas are uncommon in dogs and little is known about their distinct subtypes or proliferation rate. The aim of this study was to stratify 33 canine gastrointestinal lymphoma samples according to the latest World Health Organization classification and to determine the Ki67 proliferation index by manual counting, digital image analysis and visual estimation. The Ki67 index was then correlated with subtype, immunophenotype, mitotic index, grade and tumour location. The mitotic index correlated positively with the Ki67 index. A significantly higher number of Ki67-positive cells was found in enteropathy-associated T-cell lymphoma type I and in diffuse large B-cell lymphoma compared with enteropathy-associated T-cell lymphoma type II. There was also a significant difference in Ki67 immunolabelled cells between grade 1 and grade 2 lymphomas. Moderate agreement was found between the Ki67 index as obtained by manual counting and visual estimation, but there was strong agreement between manual counting and digital image analysis. The user-friendly digital imaging system used in this study could have potential for future determination of the Ki67 index in lymphoid neoplasms.


Assuntos
Doenças do Cão , Neoplasias Gastrointestinais , Linfoma Difuso de Grandes Células B , Animais , Proliferação de Células , Cães , Neoplasias Gastrointestinais/veterinária , Antígeno Ki-67 , Linfoma Difuso de Grandes Células B/veterinária , Índice Mitótico/veterinária
6.
Aust Vet J ; 99(5): 146-151, 2021 May.
Artigo em Inglês | MEDLINE | ID: mdl-33565080

RESUMO

OBJECTIVES: The objective of this retrospective study was to evaluate the outcome of dogs when grade II mast cell tumour (MCT) with low mitotic index (MI) and high Ki67 were treated with adjuvant lomustine. ANIMALS: Client owned dogs with spontaneously occurring disease treated with adjuvant chemotherapy for grade II mast cell tumour with low MI (≤5/10HPF) and high Ki67 (>1.8%) with no evidence of metastatic disease at presentation. PROCEDURES: Lomustine was administered every 3 weeks with three or four planned cycles. Response to treatment was assessed by regular re-staging ultrasound with or without cytopathological examination of liver and spleen or through medical records from the referring veterinarian. Disease-free interval (DFI) and median survival time (MST) were calculated using Kaplan-Meier method. RESULTS: Twenty-one dogs were included. All dogs underwent surgical excision and two dogs received adjuvant radiotherapy. None of the patients developed local recurrence. Three dogs (14.3%) developed metastatic disease. The DFI of these dogs was 141, 186 and 223 days. Median follow-up period of the whole study population was 1112 days (358-2619). MST for patients with metastatic disease was 417 days. MST of the whole group was not reached. One-year and 2-year survivals were 95.2% and 90.5%, respectively. CONCLUSIONS AND CLINICAL RELEVANCE: This study population had low rates of tumour recurrence and improved survival compared to previously published data of similar population of dogs with low MI/high Ki67 MCT without adjuvant chemotherapy.


Assuntos
Doenças do Cão , Lomustina , Animais , Doenças do Cão/tratamento farmacológico , Doenças do Cão/cirurgia , Cães , Antígeno Ki-67 , Lomustina/uso terapêutico , Mastócitos , Índice Mitótico/veterinária , Estudos Retrospectivos
7.
Vet Pathol ; 58(2): 243-257, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-33371818

RESUMO

Counting mitotic figures (MF) in hematoxylin and eosin-stained histologic sections is an integral part of the diagnostic pathologist's tumor evaluation. The mitotic count (MC) is used alone or as part of a grading scheme for assessment of prognosis and clinical decisions. Determining MCs is subjective, somewhat laborious, and has interobserver variation. Proposals for standardizing this parameter in the veterinary field are limited to terminology (use of the term MC) and area (MC is counted in an area measuring 2.37 mm2). Digital imaging techniques are now commonplace and widely used among veterinary pathologists, and field of view area can be easily calculated with digital imaging software. In addition to standardizing the methods of counting MF, the morphologic characteristics of MF and distinguishing atypical mitotic figures (AMF) versus mitotic-like figures (MLF) need to be defined. This article provides morphologic criteria for MF identification and for distinguishing normal phases of MF from AMF and MLF. Pertinent features of digital microscopy and application of computational pathology (CPATH) methods are discussed. Correct identification of MF will improve MC consistency, reproducibility, and accuracy obtained from manual (glass slide or whole-slide imaging) and CPATH approaches.


Assuntos
Software , Animais , Amarelo de Eosina-(YS) , Hematoxilina , Índice Mitótico/veterinária , Reprodutibilidade dos Testes
8.
J Comp Pathol ; 178: 16-21, 2020 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-32800103

RESUMO

Squamous cell carcinoma (SCC) is a frequent malignant neoplasm of the skin that usually arises from areas of solar dermatosis. It is characterized by local invasiveness and regional lymph node metastasis, mainly in poorly differentiated tumours. Galectin-3 (Gal-3) is a lectin that is expressed in the nucleus or cytoplasm and has been identified as a prognostic tool for human neoplasms. The purpose of this study was to characterize Gal-3 expression in canine cutaneous SCCs and to investigate its relationship with tumour differentiation and cell proliferation indices. Immunohistochemical analysis of 50 SCCs for Gal-3 revealed no correlation between the localization or intensity of immunolabelling, or number of immunopositive cells, with histological grade of tumour or proliferative activity. The results suggest that Gal-3 expression is not a reliable prognostic marker for cutaneous SCC in dogs.


Assuntos
Carcinoma de Células Escamosas/veterinária , Doenças do Cão , Galectina 3/metabolismo , Animais , Biomarcadores Tumorais , Carcinoma de Células Escamosas/patologia , Proliferação de Células , Cães , Imuno-Histoquímica/veterinária , Índice Mitótico/veterinária , Gradação de Tumores/veterinária , Prognóstico , Neoplasias Cutâneas/patologia , Neoplasias Cutâneas/veterinária
9.
J Small Anim Pract ; 61(7): 449-457, 2020 07.
Artigo em Inglês | MEDLINE | ID: mdl-32715502

RESUMO

OBJECTIVES: To describe the clinicopathological and genetic characteristics of mast cell tumours in dogs less than 12 months old. MATERIALS AND METHODS: Retrospective review of dogs aged less than 12 months when diagnosed with mast cell tumours at three referral hospitals in the UK. RESULTS: Sixteen pure-bred dogs were included, of which 11 were female. The median age at first presentation and diagnosis were 7.6 and 9 months, respectively. In 13 dogs the mast cell tumours were cutaneous and in three they were subcutaneous. Four cutaneous mast cell tumours were described as high-grade (Patnaik or Kiupel) and nine were Patnaik grade II; three had mitotic index of >5 in 10 high-power fields. Of the three subcutaneous tumours, two had an infiltrative growth pattern and one had mitotic index of 10 per 10 high-power fields. Of 10 tested dogs, seven had c-kit mutations in exon 11 and Ki-67 score was above the cut-off value in nine. Four of 12 cases showed evidence of metastasis in the regional lymph nodes. After varying treatment protocols, all patients were alive and disease free at a median of 1115 days after diagnosis. CLINICAL SIGNIFICANCE: The prognosis of mast cell tumours in dogs less than a year old appears better than the adult counterparts, even without extensive treatment.


Assuntos
Doenças do Cão , Neoplasias Cutâneas/veterinária , Animais , Cães , Feminino , Mastócitos , Índice Mitótico/veterinária , Prognóstico , Estudos Retrospectivos
10.
Vet Pathol ; 57(2): 214-226, 2020 03.
Artigo em Inglês | MEDLINE | ID: mdl-31808382

RESUMO

Mitotic count (MC) is an important element for grading canine cutaneous mast cell tumors (ccMCTs) and is determined in 10 consecutive high-power fields with the highest mitotic activity. However, there is variability in area selection between pathologists. In this study, the MC distribution and the effect of area selection on the MC were analyzed in ccMCTs. Two pathologists independently annotated all mitotic figures in whole-slide images of 28 ccMCTs (ground truth). Automated image analysis was used to examine the ground truth distribution of the MC throughout the tumor section area, which was compared with the manual MCs of 11 pathologists. Computerized analysis demonstrated high variability of the MC within different tumor areas. There were 6 MCTs with consistently low MCs (MC<7 in all tumor areas), 13 cases with mostly high MCs (MC ≥7 in ≥75% of 10 high-power field areas), and 9 borderline cases with variable MCs around 7, which is a cutoff value for ccMCT grading. There was inconsistency among pathologists in identifying the areas with the highest density of mitotic figures throughout the 3 ccMCT groups; only 51.9% of the counts were consistent with the highest 25% of the ground truth MC distribution. Regardless, there was substantial agreement between pathologists in detecting tumors with MC ≥7. Falsely low MCs below 7 mainly occurred in 4 of 9 borderline cases that had very few ground truth areas with MC ≥7. The findings of this study highlight the need to further standardize how to select the region of the tumor in which to determine the MC.


Assuntos
Doenças do Cão/patologia , Técnicas Histológicas/veterinária , Neoplasias Cutâneas/veterinária , Animais , Contagem de Células/veterinária , Cães , Processamento de Imagem Assistida por Computador , Mastócitos/patologia , Índice Mitótico/veterinária , Gradação de Tumores/veterinária , Variações Dependentes do Observador , Patologistas , Neoplasias Cutâneas/patologia , Software
12.
J Vet Intern Med ; 32(6): 2045-2053, 2018 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-30307656

RESUMO

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are uncommon intestinal neoplasms in the dog. Literature regarding adjunctive therapy for GISTs in dogs is sparse. High-risk GISTs in humans respond to tyrosine kinase inhibition in the adjuvant setting. OBJECTIVES: To review cases of toceranib phosphate use in dogs with GISTs and provide initial assessment of possible biological activity. A secondary aim was to evaluate patient and tumor characteristics for possible prognostic value. ANIMALS: Twenty-seven dogs with confirmed GISTs based on histopathology and immunohistochemistry treated with toceranib. METHODS: Retrospective study in which cases of toceranib use in dogs with GIST were solicited using the American College of Veterinary Internal Medicine Oncology and Small Animal Internal Medicine listservs. RESULTS: Five of 7 dogs with gross disease experienced clinical benefit (71%; 3 complete responses, 1 partial response, 1 stable disease). These included 2 dogs with durable responses after toceranib discontinuation. Median progression-free interval (PFI) in dogs with gross disease was 110 weeks (range, 36-155 weeks). Median PFI in dogs with microscopic disease was 67 weeks (range, 9-257 weeks). Metastasis at diagnosis (P = 0.04) and high mitotic index (P < 0.001) were associated with shorter PFI in toceranib-treated dogs. CONCLUSIONS AND CLINICAL IMPORTANCE: Biological activity of toceranib is evident in dogs with gross disease. Metastasis of GIST at diagnosis, as well as high tumor mitotic index, was associated with shorter PFI in toceranib-treated dogs. Larger studies are needed to define postsurgical risk and refine the use of toceranib in dogs with gross and microscopic GIST.


Assuntos
Antineoplásicos/uso terapêutico , Doenças do Cão/tratamento farmacológico , Neoplasias Gastrointestinais/veterinária , Tumores do Estroma Gastrointestinal/veterinária , Indóis/uso terapêutico , Pirróis/uso terapêutico , Animais , Doenças do Cão/diagnóstico , Doenças do Cão/patologia , Cães , Feminino , Neoplasias Gastrointestinais/diagnóstico , Neoplasias Gastrointestinais/tratamento farmacológico , Neoplasias Gastrointestinais/patologia , Tumores do Estroma Gastrointestinal/diagnóstico , Tumores do Estroma Gastrointestinal/tratamento farmacológico , Tumores do Estroma Gastrointestinal/patologia , Masculino , Índice Mitótico/veterinária , Prognóstico , Intervalo Livre de Progressão , Estudos Retrospectivos
13.
Vet Comp Oncol ; 16(4): 535-543, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29989314

RESUMO

A previous study found that minichromosome maintenance protein 7 (MCM7) score was associated with prognosis in dogs with cutaneous mast cell tumours (MCTs) independent of histological grade. The primary aim of this study was to validate this score in a different cohort of dogs focusing exclusively on patients with Patnaik intermediate grade MCTs treated with surgery alone and followed for a minimum of 1 year. A secondary aim was to evaluate the prognostic performance of MCM7 in relation to Kiupel histological grade, mitotic index (MI) and Ki67 index in the same cohort of dogs. Ninety dogs were identified, 82 were low Kiupel grade and 8 were high Kiupel grade. Seventy-two dogs were alive after a median follow-up of 1136 days and 18 dogs died of MCT-related causes after a median of 116 days. A MI threshold of 5 was associated with a sensitivity of 0.39 and a specificity of 0.99 in predicting MCT-related death; for Ki67 a threshold of 0.018 was associated with a sensitivity of 0.78 and a specificity of 0.83; and for MCM7 a threshold of 0.18 gave a sensitivity of 0.83 and a specificity of 0.86. Combining MI, Ki67 and MCM7 showed an improved accuracy of predicting death compared with each individual variable. Therefore, performing Ki67 and MCM7 in dogs with GII MCT, low Kiupel grade and low MI might be a consideration.


Assuntos
Doenças do Cão/diagnóstico , Antígeno Ki-67/metabolismo , Mastocitose Cutânea/veterinária , Componente 7 do Complexo de Manutenção de Minicromossomo/metabolismo , Índice Mitótico/veterinária , Animais , Biomarcadores Tumorais/metabolismo , Doenças do Cão/mortalidade , Doenças do Cão/patologia , Cães , Feminino , Masculino , Mastocitose Cutânea/diagnóstico , Mastocitose Cutânea/mortalidade , Mastocitose Cutânea/patologia , Prognóstico , Sensibilidade e Especificidade , Pele/patologia
14.
Vet Comp Oncol ; 16(4): 518-528, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29961964

RESUMO

Metastatic rates and survival times of canine anal sac gland adenocarcinomas (ASGACs) vary among studies, making prognostication difficult. Little is known about the prognostic significance of histopathology of ASGACs. This retrospective study investigated associations between histological features, clinical presentation and outcome for 39 ASGACs. Most tumours were incompletely excised (62%) and had moderate to marked peripheral infiltration (74%). The predominant growth pattern was solid, tubules/rosettes/pseudorosettes and papillary in 49%, 46% and 5% of the cases, respectively. Nuclear pleomorphism was either moderate (77%) or mild (23%). Necrosis and lymphovascular invasion were present in 54% and 10% of the cases, respectively. All histological features except mitotic count and necrosis were associated with nodal metastasis at presentation. A statistically significant poorer outcome was identified for tumours with a solid growth pattern, moderate or marked peripheral infiltration, necrosis and lymphovascular invasion. These results need further validation in a larger cohort of dogs.


Assuntos
Adenocarcinoma/veterinária , Neoplasias das Glândulas Anais/patologia , Sacos Anais/patologia , Doenças do Cão/patologia , Adenocarcinoma/diagnóstico , Adenocarcinoma/patologia , Adenocarcinoma/cirurgia , Neoplasias das Glândulas Anais/diagnóstico , Neoplasias das Glândulas Anais/mortalidade , Neoplasias das Glândulas Anais/cirurgia , Animais , Intervalo Livre de Doença , Doenças do Cão/diagnóstico , Doenças do Cão/mortalidade , Doenças do Cão/cirurgia , Cães , Feminino , Masculino , Margens de Excisão , Índice Mitótico/veterinária , Prognóstico , Estudos Retrospectivos , Análise de Sobrevida
15.
J Vet Pharmacol Ther ; 41(1): e45-e48, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28833247

RESUMO

Canine histiocytic sarcoma (HS) is an aggressive and highly metastatic tumor. Previously, the kinase inhibitor dasatinib was shown to have potent growth inhibitory activity against HS cells in vitro, possibly via targeting the EPHA2 receptor. Here, the in vivo effect of dasatinib in HS cells was investigated using a xenograft mouse model. Moreover, the expression status of EPHA2 was examined in six HS cell lines, ranging from insensitive to highly sensitive to dasatinib. In the HS xenograft mouse model, dasatinib significantly suppressed tumor growth, as illustrated by a decrease in mitotic and Ki67 indices and an increase in apoptotic index in tumor tissues. On Western blot analysis, EPHA2 was only weakly detected in all HS cell lines, regardless of sensitivity to dasatinib. Dasatinib likely results in the inhibition of xenograft tumor growth via a mechanism other than targeting EPHA2. The findings of this study suggest that dasatinib is a targeted therapy drug worthy of further exploration for the treatment of canine HS.


Assuntos
Antineoplásicos/farmacologia , Dasatinibe/farmacologia , Doenças do Cão/tratamento farmacológico , Sarcoma Histiocítico/veterinária , Receptor EphA2/metabolismo , Animais , Apoptose/efeitos dos fármacos , Western Blotting/veterinária , Linhagem Celular Tumoral , Modelos Animais de Doenças , Cães , Feminino , Sarcoma Histiocítico/tratamento farmacológico , Técnicas In Vitro , Camundongos , Camundongos Endogâmicos BALB C , Índice Mitótico/veterinária , Transplante de Neoplasias/veterinária
16.
Poult Sci ; 96(12): 4399-4408, 2017 Dec 01.
Artigo em Inglês | MEDLINE | ID: mdl-29053871

RESUMO

The pioneering study of Eyal-Giladi and Kochav (EG&K; Eyal-Giladi and Kochav, 1976) on the early developmental stages-from fertilization, through oviposition, to the gastrulation process-set the standard for characterizing chicken embryos, and has been used in numerous studies over the years. During uterine development, the chicken embryo undergoes dramatic changes, extremely rapid cell cycles, massive cell death, and axial determination processes. However, once the egg is laid, the temperature drops and the embryo enters into a diapause-like state. This phenomenon is utilized to store fertile eggs prior to incubation. The ability to resume development to hatching, following storage, relies on several factors, including the number of living cells and the embryonic developmental stage. These factors are highly influenced by the storage conditions-mainly duration and temperature. Thus, to study the effects of storage conditions on embryonic viability, a comprehensive characterization of the starting point-shortly after oviposition-is needed. In this study, we characterized freshly laid broiler eggs from Ross 308 flocks for embryonic developmental stage, total cell count, and cell viability. Using the novel high-resolution episcopic microscopy (HREM) system, we show, for the first time, high-resolution 3D morphological models of blastoderms which allow for highly accurate embryonic staging. Staging was also done under a dissecting microscope thus allowing for a direct side-by-side comparison of the two methods. Analysis of freshly laid blastomeres showed that the total nucleus count increases with developmental stage from ∼60,000 at stage X EG&K to ∼130,000 at stage XIII EG&K, whereas the proportion of mitotic index and dying cells at oviposition are ∼2% and ∼5%, respectively. Moreover, staging embryos from young and old flocks revealed that the blastoderms of the old flocks are more developed. Specifically, the predominant embryonic stages were XI and XII EG&K in young and old flocks, respectively. Collectively, we characterized parameters that can serve to analyze the maladaptive effects of prolonged storage under various conditions on embryo survival.


Assuntos
Criação de Animais Domésticos/métodos , Blastoderma/fisiologia , Embrião de Galinha/fisiologia , Galinhas/fisiologia , Óvulo/crescimento & desenvolvimento , Animais , Blastoderma/citologia , Blastoderma/embriologia , Contagem de Células/métodos , Sobrevivência Celular , Embrião de Galinha/embriologia , Embrião de Galinha/crescimento & desenvolvimento , Embriologia/métodos , Índice Mitótico/veterinária
17.
BMC Vet Res ; 13(1): 111, 2017 Apr 20.
Artigo em Inglês | MEDLINE | ID: mdl-28427401

RESUMO

BACKGROUND: Ki67 index, tumor associated macrophages (TAMs) and mast cells (MCs) are associated with malignancies in animal and human neoplasms including colorectal carcinomas (CRC). This has not been assessed in canine CRC. Given similar genetic abnormalities between human and canine CRC, we assessed Ki-67 and mitotic indices, TAMs and MC count (MCC) in canine CRC (n = 17). TAMs and MCC were compared with those in adenomas (n = 13) and control (n = 9). RESULTS: Ki-67 index in CRC (17.13 ± 11.50) was strongly correlated (r = 0.98, p < 0.05) with mitotic index (3.52 ± 1.80). MCC was higher (p < 0.05) in CRC (6.30 ± 3.98) than in adenomas (0.78 ± 0.77) and control (0.35 ± 0.33). The results suggest that Ki-67 index and MCC are associated with malignancy in canine CRC. Higher average TAMs were counted in adenomas (21.30 ± 20.70) and in CRC (11.00 ± 9.82) than in the control (7.69 ± 7.26), although the differences were not significant (p > 0.05). CONCLUSION: Ki-67 index, TAMs and MCC in canine CRC were recorded for the first time in this study. Ki-67 index and MCC are associated with malignancy in canine CRC. Quantitative assessment of MCs and Ki-67 coupled with mitotic index and other clinical parameters may help in evaluating malignancy in canine CRC. TAMs likely play a role in the development of canine colorectal tumors. Further studies to determine the clinical significance of these parameters for prognostic, chemo-preventive and chemotherapeutic purposes in canine colorectal tumors are recommended.


Assuntos
Neoplasias Colorretais/veterinária , Doenças do Cão/imunologia , Antígeno Ki-67/metabolismo , Macrófagos/imunologia , Mastócitos/imunologia , Adenoma/imunologia , Adenoma/veterinária , Animais , Carcinoma/imunologia , Carcinoma/veterinária , Neoplasias Colorretais/imunologia , Cães , Macrófagos/metabolismo , Mastócitos/metabolismo , Índice Mitótico/veterinária
18.
Vet Comp Oncol ; 15(4): 1280-1294, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27578604

RESUMO

Limited veterinary literature is available regarding prognostic markers for canine renal cell carcinoma (CRCC). We retrospectively evaluated COX-2 expression, histological and clinical features associated with prognosis of CRCC. Sixty-four cases post-nephrectomy were included, 54 had histopathological assessment and 30 had COX-2 immunostaining performed. Eight dogs (13%) had metastatic disease at initial diagnosis. Twenty-seven dogs (42%) received adjuvant therapy after nephrectomy. On univariate analysis, COX-2 expression, mitotic index (MI), histologic type, vascular invasion, neoplastic invasiveness and metastasis at diagnosis were significantly associated with overall median survival time (MST). COX-2 score (COX-2 score > 3 MST 420 days versus 1176 days if COX-2 score <3; P = 0.011) and MI (MI > 30 MST 120 days versus 540 days for MI < 30; P = 0.003) were the only variables associated with CRCC outcome on multivariate analysis. The addition of MI and COX-2 immunostaining to standard histopathological evaluation would help predicting outcome in CRCC patients.


Assuntos
Carcinoma de Células Renais/veterinária , Ciclo-Oxigenase 2/metabolismo , Doenças do Cão/diagnóstico , Neoplasias Renais/veterinária , Nefrectomia/veterinária , Animais , Carcinoma de Células Renais/diagnóstico , Carcinoma de Células Renais/patologia , Carcinoma de Células Renais/cirurgia , Doenças do Cão/mortalidade , Doenças do Cão/patologia , Doenças do Cão/cirurgia , Cães , Feminino , Neoplasias Renais/diagnóstico , Neoplasias Renais/patologia , Neoplasias Renais/cirurgia , Masculino , Índice Mitótico/veterinária , Invasividade Neoplásica/patologia , Prognóstico , Estudos Retrospectivos , Análise de Sobrevida , Resultado do Tratamento
19.
Vet Comp Oncol ; 15(2): 518-524, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26781433

RESUMO

Feline injection-site sarcoma (FISS) is commonly treated with surgery and radiation therapy. Despite aggressive therapy, FISS has a high recurrence rate. The true benefit of adjuvant chemotherapy is not known. DNA damage response mechanisms help protect against genomic instability but can also promote chemoresistance. In order to determine whether DNA damage is a feature of FISS, we evaluated tumour tissues with γH2AX immunohistochemistry. H2AX is phosphorylated to form γH2AX following DNA double strand breaks. Seventeen FISS specimens were evaluated prospectively. DNA damage ranged from 2.18 to33.7%, with a median of 16.2%. Significant differences were noted between cats (P < 0.0001). Mitotic index ranged from 0 to 57 with a median of 13 and did not correlate with γH2AX positivity (P = 0.2). Further studies are needed to determine if γH2AX expression may predict chemosensitivity and have independent value as a prognostic factor.


Assuntos
Doenças do Gato/etiologia , Dano ao DNA , Sarcoma/veterinária , Neoplasias de Tecidos Moles/veterinária , Animais , Doenças do Gato/metabolismo , Doenças do Gato/patologia , Gatos , Feminino , Histonas/metabolismo , Injeções/efeitos adversos , Injeções/veterinária , Masculino , Índice Mitótico/veterinária , Sarcoma/etiologia , Sarcoma/metabolismo , Sarcoma/patologia , Neoplasias de Tecidos Moles/etiologia , Neoplasias de Tecidos Moles/metabolismo , Neoplasias de Tecidos Moles/patologia
20.
Vet Pathol ; 53(4): 788-91, 2016 07.
Artigo em Inglês | MEDLINE | ID: mdl-26792846

RESUMO

Choroid plexus tumors (CPTs) are reported with an increasing incidence in dogs, and they call for a reexamination of histologic features and criteria of classification corresponding to their biological behavior. In this study, the human World Health Organization classification was applied to 16 canine CPTs, and the expression of molecules involved in neoplastic cell adhesion (E-cadherin, N-cadherin), invasion (doublecortin), and proliferation (Ki-67) was investigated. Mitotic index was found to be the main criterion for grading CPTs. Cell density and multilayering of papillae were also statistically associated with histologic grade. Intraventricular spread and parenchymal invasion was observed for tumors showing histologic benign features. E-cadherin was expressed in all CPT grades, independent of tumor invasion. N-cadherin immunolabeling was more expressed in grade I than high-grade CPTs, whereas doublecortin expression was not detected in CPTs. An increasing proliferative activity was observed in relation with histologic grade.


Assuntos
Caderinas/metabolismo , Neoplasias do Plexo Corióideo/veterinária , Doenças do Cão/classificação , Animais , Neoplasias do Plexo Corióideo/classificação , Neoplasias do Plexo Corióideo/metabolismo , Neoplasias do Plexo Corióideo/patologia , Doenças do Cão/metabolismo , Doenças do Cão/patologia , Cães , Feminino , Imuno-Histoquímica/veterinária , Masculino , Índice Mitótico/veterinária , Gradação de Tumores/veterinária
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA